Discover the Latest Breakthroughs in Endocrinology at ADA Congress: Learn about the First Oral Non-Peptide GLP-1 Agonist and its Impressive Weight Reduction Results!

by Alexandra Hartman Editor-in-Chief June 25, 2023

written by Alexandra Hartman Editor-in-Chief June 25, 2023

2023-06-25 14:19:43

Endocrinology – ADA Congress

ADA Congress

Orforglipron, the first oral non-peptide GLP-1 agonist, manages to reduce weight by up to 14.7% without restricting eating and drinking hours.

The new oral GLP-1 agonists would be chronic treatments with a similar safety profile to injectables. Photo: SHUTTERSTOCK
1687722754
#Advances #generation #orals #obesity

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

Discover the Latest Breakthroughs in Endocrinology at ADA Congress: Learn about the First Oral Non-Peptide GLP-1 Agonist and its Impressive Weight Reduction Results!

Share this:

Related

Pray for the Recovery of Lebanese Red Cross Secretary-General George Kettaneh

Upheaval in Russia: European Countries on High Alert as Wagner’s Paramilitaries Threaten Putin’s Government

You may also like

Leave a Comment Cancel Reply

Adblock Detected